# A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)

> **NCT02029157** · PHASE3 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 386 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** ARQ197
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02029157
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 386 (ACTUAL)
- **Last updated:** 2017-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029157, "A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02029157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*